IN8bio, Inc. Form 8-K Summary
Business context and reporting period
IN8bio, Inc., a Delaware biotechnology company listed on the Nasdaq Global Select Market under the symbol INAB, filed this Current Report on December 9, 2021, regarding an executive appointment effective December 1, 2021. The filing does not cover a quarterly or annual financial reporting period.
Material corporate action
- The Board of Directors appointed Kate Rochlin, Ph.D. as Chief Operating Officer, effective December 1, 2021.
- Dr. Rochlin previously served as the Company’s Vice President, Operations and Innovation since December 2020 and as Associate Vice President of Operations and Innovation from August to December 2020.
- Her compensation includes an annual base salary of $400,000 and eligibility for an annual bonus equal to 40% of base salary.
- The filing reports no related-person transactions requiring disclosure under Item 404(a) of Regulation S-K.
Financial metrics, liquidity, and debt
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, balance-sheet data, or other operating financial metrics.
Guidance, outlook, risks, and unusual items
The filing provides no financial guidance, business outlook, contingencies, risk updates, or unusual accounting items. The principal disclosed change is the appointment and compensation arrangement of the new Chief Operating Officer.
Facts investors should verify
- Confirm the effective date of Dr. Rochlin’s appointment: December 1, 2021.
- Verify the annual base salary of $400,000 and the 40% target bonus eligibility.
- Review subsequent filings for additional equity awards, employment terms, or changes in executive compensation.
- Consult the Company’s periodic financial filings for cash runway, operating losses, funding requirements, and development-program risks, which are not addressed in this 8-K.